Drug
Polyethylene glycol 400 clinical trials
Also written PEG 400.
A product of Polyethylene Glycols; its studies count on that page too.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2001
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 4
- 3
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 5
Bp Consulting, Inc (3) · Medical University of South Carolina (1) · Boehringer Ingelheim (1) · University of Faisalabad (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses polyethylene glycol 400 is read from its arms, and is right about nine times in ten.
Testing it · 6
- Corneal Thickness Changes in Patient Undergoing Dry Eye ManagmentStatus unknownNot applicableUniversity of FaisalabadNCT04970329Written as Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,
- Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye SymptomsCompletedNot applicableMedical University of South CarolinaNCT00565669Written as Systane
- Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human SubjectsCompletedPhase 1Boehringer IngelheimNCT02260076Written as PEG 400
- Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual QualityCompletedPhase 4Bp Consulting, IncNCT00622037Written as PEG-400 based artificial tear
- Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK).CompletedPhase 4Bp Consulting, IncNCT00620893Written as Systane
- Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of VisionCompletedPhase 4Bp Consulting, IncNCT00627302Written as PEG-400
Given in every arm · 1 — polyethylene glycol 400 is usual care beside what is tested
As the comparator · 7 — what is tested is compared with polyethylene glycol 400
- Fluoxetine for Refractory ConstipationCompletedNot applicableZhifeng Zhao, PhDNCT06750445Written as Polyethylene Glycol 400 0.4%
- Artificial Tears Study in Mild to Moderate Dry Eye PatientsCompletedPhase 2Abbott Medical OpticsNCT00607776Written as Systane
- Evaluation of Ocular Comfort With ISTA Tears vs SystaneCompletedNot applicableBausch & Lomb IncorporatedNCT01650584Written as Systane
- Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye DropsCompletedNot applicableCalm Water Therapeutics LLCNCT05660681Written as polyethylene glycol 400 0.4%/propylene glycol 0.3%
- Colon Cleansing Efficacy With 1L vs. 2L vs. 4L-PEG for Colonoscopy Among InpatientsStatus unknownPhase 4University of BolognaNCT04708366Written as Macrogol 400
- Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry EyeCompletedPhase 3Laboratorios Sophia S.A de C.V.NCT01657253Written as Systane
- Tear Film Break-up Time After Instillation of Artificial TearsCompletedNot applicableCalm Water Therapeutics LLCNCT00681265Written as polyethylene glycol 400/propylene glycol
Codes
What other systems call polyethylene glycol 400 · ClinicalTrials.gg INT000171
- MeSH (NLM) C000595213polyethylene glycol 400One source NLM
- UNII (FDA) B697894SGQPOLYETHYLENE GLYCOL 400Confirmed FDA, NLM, Wikidata
- NCI Thesaurus C84080Polyethylene Glycol 400One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000595213 | polyethylene glycol 400 | One source NLM |
| UNII (FDA) | B697894SGQ | POLYETHYLENE GLYCOL 400 | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C84080 | Polyethylene Glycol 400 | One source FDA |
Also registered as polyethylene glycol 18000 (UNII 2AS3MDK9CB).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.